Leishmania major: In vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod

Experimental Parasitology

Volumn 116, Issue 2, 2007, Pages 156-162

  El On, Joseph ^a   Bazarsky, Elina ^a   Sneir, Rachella ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Aldara; Amastigotes; Balb c mice; Imiquimod; IMQ; In vitro and In vivo activity; Leishmania major; Leshcutan; MBCL; Methylbenzethonium chloride; Paromomycin; PR; Promastigotes; Topical treatment

Indexed keywords

IMIQUIMOD; LESHCUTAN; METHYLBENZETHONIUM CHLORIDE; PARAFFIN; PAROMOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MAJOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; BENZETHONIUM; DRUG THERAPY, COMBINATION; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; OINTMENTS; PAROMOMYCIN; RABBITS;

LEISHMANIA MAJOR; MUS;

EID: 34247130502     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2006.12.004     Document Type: Article

References (32)

1. Arana B.A., Navin T.R., Arana F.E., Berman J.D., and Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clinical Infectious Diseases 18 (1994) 381-384
2. Arana B.A., Mendoza C.E., Rizzo N.R., and Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. American Journal of Tropical Medicine and Hygiene 65 (2001) 466-470
3. Arevalo I., Ward B., Miller R., Meng T.C., Najar E., Alvarez E., Matlashewski G., and Llanos-Cuentas A. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator, Clinical. Infectious Diseases 33 (2001) 847-851
4. Bari A.U., and Rahman S.B. A therapeutic update on cutaneous leishmaniasis. Journal of College Physicians and Surgeons Pakistan 13 (2003) 471-476
5. Bogdan C., Moll H., Solbach W., and Rollinghoff M. Tumor necrosis factor alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. European Journal of Immunology 20 (1990) 1131-1135
6. Buates S., and Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Diseases 179 (1999) 1485-1494
7. Croft S.L., and Yardley V. Chemotherapy of leishmaniasis. Current Pharmaceutical Design 8 (2002) 319-342
8. El-On J., Jacobs G., and Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitology Today 4 (1988) 76-81
9. El-On J., Jacobs G.F., Witztum E., and Greenblatt C.L. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrobial Agents and Chemotherapy 26 (1984) 745-751
10. El-On J., Sulitzeanu A., and Schnur L.F. Leishmania major: resistance of promastigotes to paromomycin and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Annals of Tropical Medicine and Parasitology 85 (1991) 323-328
11. Falcoff E., Gimenez L.A., Bernabo J.C., and Bottasso O. Interferon-gamma as an immunological strategy for the treatment of human leishmaniasis. Medicina Buenos Aires 54 (1994) 265-271
12. Ferreira L.S., Souza R.C.C., Nascimento D.S., Fernandes A.P., and Ferreira L.A.M. Desenvolvimento de formulacoes hidrofilicas para tratamento topico da leishmaniose cutanea. Revista da Sociedade Brasileira de Medicina Tropical 35 (2002) S113-S117
13. Gamier T., and Croft C.L. Topical treatment of cutaneous leishmaniasis. Current Opinion in Investigating Drugs 3 (2002) 538-544
14. Goncalves G.S., Fernandes A.P., Souza R.C.C., Cardoso J.E., de Oliveira-Silva F., Maciel F.C., Rabello A., and Ferreira L.A.M. Activity of paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) brziliensis. Acta Tropica 93 (2005) 161-167
15. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., and Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. Journal of Experimental Medicine 177 (1993) 1505-1509
16. Lee S.A., and Hasbun R. Therapy of cutaneous leishmaniasis. International Journal of Infectious Diseases 7 (2003) 86-93
17. Liew F.Y., Li Y., and Millott M.J. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. Immunology 145 (1990) 4306-4310
18. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-320
19. Machado-Pinto J., Pinto J., da Costa C.A., Genaro O., Marques M.J., Modabber F., and Mayrink W. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial. International Journal of Dermatology 41 (2002) 73-78
20. Magill A.J., Grogl M., Gasse R.A., Sun W., and Oster C.N. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Strom. New England Journal of Medicine 328 (1993) 1383-1387
21. Mayrink W., Botelho A.C., Magalhaes P.A., Batista S.M., Lima Ade O., Genaro O., Costa C.A., Melo M.N., Michalick M.S., Williams P., Dias M., and Caiaffa W.T. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Revista de Sociedade. Brasileira de Medicina Tropical 39 (2006) 14-21
22. Moll H. The role of dentritic cells at the early stages of Leishmania infection. Advances in Experimental Medicine and Biology 479 (2000) 163-173
23. Nashed B.F., Maekawa Y., Takashima M., Zhang T., Ishii K., Dainichi T., Ishikawa H., Sakai T., Hisaeda H., and Himeno K. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major. Microbes and Infection 2 (2000) 1435-1443
24. Seeberger J., Daoud S., and Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. International Journal of Dermatology 42 (2003) 576-579
25. Shah J.A., Darrah P.A., Ambrozak D.R., Turon T.N., Mendez S., Kirman J., Wu C.Y., Glaichenhaus N., and Seder R.A. Dentritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. Journal of Experimental Medicine 198 (2003) 281-291
26. Skinner Jr. R.B. Imiquimod. Dermatology Clinical 21 (2003) 291-300
27. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., and Fischer C. Treatment of cutaneous leishmaniasis with miltefosine, an oral agent. Clinical Infectious Diseases 33 (2001) E57-E61
28. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. International Journal of Radiation Oncology Biology and Physics 5 (1979) 85-91
29. Testerman T.L., Gerster J.F., Imberston L.M., Reiter M.J., Miller R.L., Gibson S.J., Wagner T.L., and Tomai M.A.J. Cytokine induction by the immunomodulators imiquimod and S-27609. Journal of Leukocyte Biology 58 (1995) 365-372
30. von Stebut E., Belkaid Y., Nguyen B.V., Cushing M., Sacks D.L., and Udey M.C. Leishmania major-infected murine langerhans cell-like dentritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis. European Journal of Immunology 30 (2000) 3498-3506
31. Wei X.Q., Niedbala W., Xu D., Luo Z.X., Pollock K.G., and Brewer J.M. Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major. Infection Immunology Letters 15 (2004) 35-37
32. Weinrauch L., Cawich G., Craig F., Sosa J., and El-On J. Topical treatment of new world cutaneous leishmaniasis in Belize: a clinical study. Journal of the American Academy of Dermatology 29 (1993) 443-446